Efficacy and Safety of Lercanidipine Combination in Hypertensive Patients参考訳:高血圧患者におけるレルカニジピン併用療法の有効性と安全性
Athanasios J. Manolis, Manolis S. KallistratosORCID 0000-0002-8256-4218責任著者, Miguel CamafortORCID 0000-0002-8669-6410, Antonio Coca
- 種別
- 研究論文
- 掲載日
- ページ
- 38-49
要旨(Efficacy and Safety of Lercanidipine Combination in Hypertensive Patients)
Calcium channel blockers (CCBs) are widely used for the treatment of arterial hypertension, but they differ in terms of pharmacology, tolerability, and pleiotropic actions. Lercanidipine, a highly lipophilic third generation dihydropyridine, reduces blood pressure (BP) effectively as monotherapy and in combination without inferiority to other major antihypertensive classes. We systematically searched PubMed and the Cochrane Library (last update: September 1, 2025) and screened reference lists for additional studies. Evidence from dose finding trials, randomized controlled studies, large observational cohorts, and meta analyses shows clinically meaningful reductions in office, home, and ambulatory BP with lercanidipine, including in patients with diabetes, obesity, chronic kidney disease, or high cardiovascular (CV) risk. Fixed-dose combinations with renin angiotensin system blockers (e.g., enalapril) provide greater BP reductions than monotherapy and are associated with favorable neurometabolic profiles. Beyond BP control, lercanidipine improves central hemodynamics and arterial stiffness, favors endothelial biology, and contributes to left ventricular hypertrophy regression. Across comparative trials, lercanidipine is generally better tolerated than older dihydropyridines, with lower rates of vasodilatory adverse events and less sympathetic activation, while discontinuations due to adverse events are uncommon. Overall, lercanidipine, particularly within single-pill combinations, offers effective, durable BP lowering across diverse patient profiles with a favorable safety and tolerability profile and pleiotropic benefits that extend beyond BP reduction.
引用方法
RIS/BibTeXを表示
TY - JOUR AU - Athanasios J. Manolis AU - Manolis S. Kallistratos AU - Miguel Camafort AU - Antonio Coca TI - Efficacy and Safety of Lercanidipine Combination in Hypertensive Patients JO - Journal of Hypertension and Cardiology SN - 2329-9487 VL - 3 IS - 4 SP - 38 EP - 49 PY - 2025 DA - 2025-12-02 DO - 10.14302/issn.2329-9487.jhc-25-5778 UR - https://doi.org/10.14302/issn.2329-9487.jhc-25-5778 PB - Open Access Pub ER -
@article{jhc2267,
author = {Athanasios J. Manolis and Manolis S. Kallistratos and Miguel Camafort and Antonio Coca},
title = {Efficacy and Safety of Lercanidipine Combination in Hypertensive Patients},
journal = {Journal of Hypertension and Cardiology},
volume = {3},
number = {4},
pages = {38--49},
year = {2025},
issn = {2329-9487},
doi = {10.14302/issn.2329-9487.jhc-25-5778},
url = {https://doi.org/10.14302/issn.2329-9487.jhc-25-5778}
}